Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
587 hedge funds and large institutions have $25.3B invested in Alexion Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 92 funds opening new positions, 225 increasing their positions, 209 reducing their positions, and 95 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 225 | Existing positions reduced: 209
3% less first-time investments, than exits
New positions opened: 92 | Existing positions closed: 95
1% less funds holding
Funds holding: 595 → 587 (-8)
10% less call options, than puts
Call options by funds: $420M | Put options by funds: $468M
11% less funds holding in top 10
Funds holding in top 10: 19 → 17 (-2)
16% less capital invested
Capital invested by funds: $30B → $25.3B (-$4.75B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$168M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$153M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$128M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$88.4M |
| 5 |
Ninety One (UK)
London,
United Kingdom
|
+$85.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$165M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$156M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$155M |
| 4 |
TP
Third Point
New York
|
-$140M |
| 5 |
TCP
Tourbillon Capital Partners
New York
|
-$119M |
ALXN Hedge Fund Activity: Q4 2017 in Review
587 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q4 2017, worth a combined $25.3B — down 16% from $30B a quarter earlier.
Sellers outnumbered buyers: 95 funds closed out of ALXN and 92 opened new positions — a net loss of 3 holders — while 209 trimmed existing stakes and 225 added.
The largest buyer was Amundi Asset Management US, adding an estimated $168M. The largest seller was BlackRock, cutting an estimated $165M.
- 587 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q4 2017, down from 595 in Q3 2017.
- Funds reported $25.3B of Alexion Pharmaceuticals stock for Q4 2017, down 16% quarter-over-quarter.
- 92 funds opened new Alexion Pharmaceuticals positions in Q4 2017 and 95 closed out, a net change of -3 holders.
- The largest Alexion Pharmaceuticals buyer in Q4 2017 was Amundi Asset Management US, an estimated $168M added.
- The largest Alexion Pharmaceuticals seller in Q4 2017 was BlackRock, an estimated $165M sold.
Based on aggregated 13F filings for Q4 2017.